## TXN: Texas Instruments Incorporated - XLK: Technology

### Executive Summary

No thesis match: MRS_10 -1.8% below STRENGTH zone (3.0-6.0%); PEG 1.52 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($168.87)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Neutral (Bullish: 1, Bearish: 0)

**1. Silicon Sovereignty: Texas Instrumentsâ€™ Sherman Mega-Site Commences Production, Reshaping the Global AI Hardware Supply Chain**
- Source: FinancialContent | 20251224T141400 | Bullish | Relevance: 100%
- Texas Instruments (Nasdaq: TXN) has officially commenced volume production at its first 300mm wafer fabrication plant (SM1) within its Sherman mega-site, a significant milestone for domestic chip manufacturing and the AI hardware supply chain. This $30 billion investment aims to provide foundational silicon for AI, focusing on advanced analog and embedded processing chips. The Sherman site will produce tens of millions of chips daily, gaining a cost advantage through 300mm wafer technology and bolstering the reliability of the AI ecosystem's hardware roadmap.

**2. James Hambro & Partners LLP Sells 35,265 Shares of Texas Instruments Incorporated $TXN**
- Source: MarketBeat | 20251224T134049 | Neutral | Relevance: 100%
- James Hambro & Partners LLP reduced its stake in Texas Instruments (NASDAQ:TXN) by 6.5% during Q3, selling 35,265 shares, and now holds 507,136 shares worth approximately $93.16 million. Analyst sentiment for Texas Instruments is mixed, with a consensus "Hold" rating and a target price of $191.49, despite recent downgrades by some firms like Goldman Sachs to "sell." Texas Instruments reported Q3 EPS of $1.48, meeting estimates, and revenue of $4.74 billion, with a Q4 guidance of $1.13-$1.39 EPS.

**3. Texas Instruments (TXN) Stock Today (Dec. 22, 2025): Sherman Fab Momentum Meets a Split Wall Street**
- Source: ts2.tech | 20251222T183555 | Neutral | Relevance: 100%
- Texas Instruments (TXN) is experiencing a modest rebound, balancing a major U.S. manufacturing milestone with questions about demand recovery and margins. The company's new Sherman SM1 fab has begun production, a significant step in its $60+ billion U.S. manufacturing plan, while analysts remain split on its short-term profitability due to capacity building ahead of demand. Investors are keenly watching industrial demand, gross margins, and the pace of the Sherman fab's ramp-up ahead of the next earnings report in late January 2026.

**4. Texas Instruments Inc. stock underperforms Monday when compared to competitors despite daily gains**
- Source: MarketWatch | 20251222T163600 | Neutral | Relevance: 100%
- On Monday, shares of Texas Instruments Inc. (TXN) increased by 1.44% to $178.82. Despite this gain and an overall positive day for the stock market, the company's stock underperformed compared to key competitors. It was the third consecutive day of gains for the stock.

**5. Legacy Wealth Asset Management LLC Grows Stock Position in Texas Instruments Incorporated $TXN**
- Source: MarketBeat | 20251222T120846 | Neutral | Relevance: 100%
- Legacy Wealth Asset Management LLC significantly increased its stake in Texas Instruments Incorporated (NASDAQ:TXN) by 119.2% in Q3, now holding 10,510 shares valued at approximately $1.931 million. Other institutional investors like Vanguard Group Inc., Jennison Associates LLC, and Invesco Ltd. also boosted their positions in the semiconductor company. Despite insider selling by a VP and a director, the stock currently holds a consensus "Hold" rating from analysts with an average target price of $191.49.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-19 | Truist Securiti | $195 | $175 | +11% |
| 2025-12-15 | Goldman Sachs | $156 | $200 | -22% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-19 | Truist Securiti | main | Hold |
| 2025-12-15 | Goldman Sachs | down | Sell |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 2 ($0.53M) |
| Sells | 4 ($0.52M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 42.3% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 8 / 2 |

**Top Holders:**
- Vanguard Group Inc: 10.6% (+1.1%)
- Blackrock Inc.: 8.5% (+0.1%)
- JPMORGAN CHASE & CO: 6.0% (+80.5%)
- State Street Corpora: 4.8% (+0.5%)
- Charles Schwab Inves: 2.5% (+3.9%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.52 elevated, pricing in significant growth expectations. Forward P/E 28.9x stretched relative to 12% growth. Quality metrics strong (ROE 30%, ROA 11%, margin 29%). Balance sheet: strong liquidity (4.5x). Institutional flow bullish (8 buying vs 2 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $161.0B |
| Beta | 0.99 |
| 52W Range | $139.95 - $221.69 |
| Short Interest | 2.2% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.52 |
| Forward P/E | 28.9 |
| Current P/E | 32.3 |
| YoY Growth | 12.0% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from -0.4% to -1.8% (-1.4% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 4.8pp (needs >3.0% for momentum thesis). Below SMA200 (0.98x), long-term trend not supportive. RSI neutral at 56. OFD pattern: +DUL (Resistance).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -1.81% (CS: 31) | Neutral |
| RSI_14 | 55.5 | Neutral |
| MACD Histogram | -0.41 | Bearish |
| vs SMA20 | 1.000x | Below |
| vs SMA50 | 1.045x | Above |
| vs SMA200 | 0.976x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $177.13
- **Stop Loss:** $168.87 (4.7% risk)
- **Target:** $185.39 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 145
- **Position Value:** $25,683.85
- **Portfolio %:** 25.68%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite supported by year-end positioning. VIX at cycle lows (13.47) and multiple sectors hitting 52-week highs indicate constructive sentiment, though breadth at 57.9% suggests selectivity remains important. Fed pause expectations and stable macro backdrop support risk assets.*

### Earnings

**Next:** 2026-01-20 (Est: $1.31)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.49 | $1.48 | -0.4% |
| 2025Q2 | $1.33 | $1.41 | +5.8% |
| 2025Q1 | $1.06 | $1.28 | +20.2% |
| 2024Q4 | $1.20 | $1.30 | +8.3% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_10*